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ABSTRACT 
Osteoporosis affects about 200 million people worldwide and is a silent disease until a fracture 
occurs. Management of osteoporosis is still a challenge that warrants further studies for estab-
lishing new prevention strategies and more effective treatment modalities. For this purpose, 
animal models of osteoporosis are appropriate tools, of which the ovariectomized rat model is 
the most commonly used. The aim of this study is to provide a 4-step guideline for inducing a 
rat model of osteoporosis by ovariectomy (OVX): (1) selection of the rat strain, (2) choosing 
the appropriate age of rats at the time of OVX, (3) selection of an appropriate surgical method 
and verification of OVX, and (4) evaluation of OVX-induced osteoporosis. This review of lit-
erature shows that (i) Sprague-Dawley and Wistar rats are the most common strains used, both 
responding similarly to OVX; (ii) six months of age appears to be the best time for inducing 
OVX; (iii) dorsolateral skin incision is an appropriate choice for initiating OVX; and (iv) the 
success of OVX can be verified 1-3 weeks after surgery, following cessation of the regular 
estrus cycles, decreased estradiol, progesterone, and uterine weight as well as increased LH and 
FSH levels. Current data shows that the responses of trabecular bones of proximal tibia, lumbar 
vertebrae and femur to OVX are similar to those in humans; however, for short-term studies, 
proximal tibia is recommended. Osteoporosis in rats is verified by lower bone mineral density 
and lower trabecular number and thickness as well as higher trabecular separation, changes that 
are observed at 14, 30, and 60 days post-OVX in proximal tibia, lumbar vertebrae and femur, 
respectively. 
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INTRODUCTION 
Osteoporosis, a skeletal-metabolic dis-
ease, is characterized by low bone mineral 
density (BMD) and deterioration of the bone 
microarchitecture (Lelovas et al., 2008; Bliuc 
et al., 2015). Osteoporosis affects about 200 
million people worldwide, including 34 % of 
women aged > 50 years (Strom et al., 2011; 
Pavone et al., 2017; Tian et al., 2017). Osteo-
porosis is a silent disease until the subject ex-
periences a fracture (Alswat, 2017; Sözen et 
al., 2017); ~40 % of women aged > 50 years 
experience an osteoporotic fracture within 
their lifetime (Stagi et al., 2013; Sözen et al., 
2017). Osteoporosis-induced fractures are as-
sociated with a high economic burden and 
also increased morbidity and mortality; thus 
developing new strategies for prevention and 
treatment of osteoporosis represent an urgent 
need (Lin et al., 2015; Pavone et al., 2017).  
Animal models of osteoporosis are suita-
ble tools for studying new prevention and 
treatment modalities. The first choice, and the 
one most commonly employed for such stud-
ies, is the ovariectomized rat model (Turner, 
2001). According to the Food and Drug Ad-
ministration guidelines, the rat model of oste-
oporosis is an excellent preclinical model for 
postmenopausal osteoporosis (Food and Drug 
Administration, 1994). The ovariectomized 
rat model of osteoporosis mimics the estrogen 
deficiency-induced bone loss and shows clin-
ical manifestations of postmenopausal osteo-
porosis (Jee and Yao, 2001; Kimmel, 2001). 
In addition, several therapeutic agents (e.g. 
estrogen and bisphosphonates) currently 
available for managing osteoporosis have 
been examined in the ovariectomized rat 
model (Hornby et al., 2003; Kavuncu et al., 
2003; Lelovas et al., 2008). 
New strategies have been assessed in the 
laboratory for treating osteoporosis, however, 
their implementation in the clinical settings 
has been inadequate. Such failure can be 
partly attributed to a number of factors, in-
cluding differences in selection of the skeletal 
sites, age of rats at the time of ovariectomy 
(OVX), and variations in the duration of the 
OVX (Liu et al., 2015). In addition, there is 
no standardized protocol for performing and 
verifying OVX with the subsequent determi-
nation of OVX-induced osteoporosis 
(Francisco et al., 2011). The aim of this study 
is to provide a practical guide for establishing 
a rat model of osteoporosis using OVX. Ad-
vantages and disadvantages of the model are 
presented and points related to human studies 
are highlighted. 
 
BONE: A BRIEF OVERVIEW  
Similar to humans, bone tissue in an adult 
rat is composed of ~60 % minerals (95 % cal-
cium and phosphorus as hydroxyapatite crys-
tals) and ~40 % organic component (90 % 
collagen type I) (Dogan and Posaci, 2002; Rai 
et al., 2005; Feng, 2009; Kenkre and Bassett, 
2018). Bone is a living and highly specialized 
connective tissue that serves a variety of func-
tions (Taichman, 2005; Clarke, 2008) includ-
ing production of blood cells, a role in loco-
motion, protection of vital organs, homeosta-
sis of calcium and phosphate, and regulation 
of acid-base balance (Taichman, 2005; 
Clarke, 2008).  
There are two major types of bone: Corti-
cal (compact) bone and trabecular (cancellous 
or spongy) bone (Clarke, 2008; Stagi et al., 
2013) that contribute mainly to mechanical 
and metabolic functions, respectively (Stagi 
et al., 2013). Diaphysis regions of the long 
bones are cortical bone (~80 % of bones) and 
the inner surface of flat bones and the end of 
long bones are  trabecular bones (~20 % of 
bones) (Riggs and Melton, 1986; Stagi et al., 
2013).  
Bones of rats are similar to those of hu-
mans, representing a dynamic tissue, which is 
constructed and reconstructed throughout the 
life by bone modeling and remodeling 
(Karsenty, 2017; Kenkre and Bassett, 2018). 
In the trabecular bones of rats, after decreas-
ing growth-related bone modeling, remodel-
ing becomes the main bone activity (Chow et 
al., 1993; Erben, 1996). This transition is as-
sociated with decreased longitudinal bone 
growth to very low rates (Jee and Yao, 2001). 
Trabecular bone transition occurs at month 3 
in the lumbar vertebrae, and between months 
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6-9 in the proximal tibia metaphysis (Jee and 
Yao, 2001). The duration of the remodeling 
cycles (includes four sequential phases of  ac-
tivation, resorption, reversal, and formation) 
in normal trabecular bones is ~200 days in hu-
mans and ~6 days in rats (Vignery and Baron, 
1980; Eriksen, 2010). 
 
OSTEOPOROSIS 
According to the World Health Organiza-
tion criteria, osteoporosis is defined as a BMD 
that ranks 2.5 standard deviation below the 
mean for young healthy subjects (a T-score of 
≤ –2.5 standard deviations) (WHO, 1994; 
WHO Scientific Group on Prevention and 
Management of Osteoporosis, 2003). Two 
categories of osteoporosis have been identi-
fied, primary and secondary. Primary osteo-
porosis is the most common form and in-
cludes postmenopausal and age-related osteo-
porosis (Komori, 2015). Age-related osteopo-
rosis most frequently affects cortical bone and 
induces somewhat gradual bone loss due to 
reduced osteoblast activity, whereas, post-
menopausal osteoporosis most frequently af-
fects the trabecular bones and induces a rela-
tively rapid bone loss due to increased osteo-
clast activity (Riggs and Melton, 1986; Duque 
and Troen, 2008).  
In the 1940s, Albright et al. reported that 
estrogen could prevent osteoporosis and in the 
1960s, the association between menopause 
and osteoporosis was identified for the first 
time (Ji and Yu, 2015). Women lose about 
50 % and 35 % of their trabecular and cortical 
bones, respectively throughout their life 
(Hunter and Sambrook, 2000). Biphasic pat-
terns of bone loss are reported for both hu-
mans and rats (Kalu, 1991); the slow phase of 
bone loss starts at age 40 years and the rapid 
phase occurs in the first 2 years after meno-
pause (Genant et al., 1982; Riggs and Melton, 
1986; Riggs et al., 1986), with the increased 
rate of bone loss stabilizing approximately 10 
years after menopause and merging thereafter 
into a continuous age-related bone loss 
(Hunter and Sambrook, 2000).  
OVARIECTOMIZED RAT MODEL  
OF OSTEOPOROSIS  
Rats often do not become menopausal un-
til 18–24 months of age, at which time they 
are termed aged (Brooks et al., 2016); there-
fore rats do not experience a natural meno-
pausal (Turner, 2001). OVX is used for induc-
tion of menopause in rats (Turner, 2001). In 
this study, we present a 4-step guideline for 
inducing a rat model of osteoporosis by OVX. 
As shown in Figure 1, this guideline provides 
a practical guide in 4 sequential steps: (1) se-
lection of the rat strain, (2) choosing the ap-
propriate age of rat at the time of OVX, (3) 
selection of surgery method and verification 
of the success of the OVX, and (4) evaluation 
of OVX-induced osteoporosis (selection of 
bone sites, bone type, time needed for induc-
ing osteoporosis) and lastly verification of os-
teoporosis in ovariectomized rats. 
 
Step 1: Selection of the rat strain  
Considerable variations exist in bone 
structure, BMD, and fragility phenotypes 
amongst Sprague-Dawley, Wistar, Brown 
Norway, Fischer 344, Lewis, and Wistar 
Kyoto rats (Turner et al., 2001). Although 
there is no head-to-head study to compare the 
effects of OVX on bone parameters in differ-
ent rat strains, Sprague-Dawley and Wistar 
rats are the most commonly used strains and 
show similar responses to OVX (Langdahl et 
al., 2016). In addition, FDA guidelines do not 
specify which strain of rat is most appropriate 
for osteoporosis studies (Hornby et al., 2003). 
Therefore, further studies are warranted to ad-
dress this issue. 
 
Step 2: Choosing the appropriate age of rat 
at the time of OVX 
Age of female rats plays a key role for 
model standardization at the time of OVX 
(Francisco et al., 2011). Rats reach sexual and 
skeletal maturity at around 2.5 and 10 months 
of age, respectively (Jee and Yao, 2001; Liu 
et al., 2015; Jiang et al., 2018). Rats aged 2-
11 months that commonly undergo OVX, can 
be divided into three groups, i.e. <6, 6-9 and 
>9 months (Kalu, 1991; Grynpas et al., 2000).
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Figure 1: Step-by-step guideline for inducing osteoporosis using an ovariectomized rat model. OVX, 
ovariectomy; LH, luteinizing hormone; FSH, follicle stimulating hormone; BMD, bone mineral density; 
Tb.N, trabecular number; Tb.Sp, trabecular separation; Tb.Th, trabecular thickness; P1NP, amino-ter-
minal propeptides of procollagen type I; CTX, carboxy-terminal cross-linking telopeptide of type I colla-
gen. 
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Rats < 6 months of age have some major 
drawbacks that limit their usefulness for oste-
oporosis research. For example, in this age 
group, the rate of longitudinal bone growth in 
the proximal tibia, caudal vertebrae and in the 
proximal femur is about 29.5, 4.10 (Erben, 
1996) and 5.5 µm per day, respectively (Li et 
al., 1991; Li and Jee, 1991; Li et al., 1997). In 
response to OVX, adverse effects such as in-
creased trabecular connectivity have been ob-
served in 3 months-old rats that may be due to 
faster growth rate in the young, compared to 
the old rats (Francisco et al., 2011). In addi-
tion, rats aged < 6 months have higher bone 
loss after OVX, lower the Haversian and tra-
becular bone remodeling and lower sensitiv-
ity of lumbar vertebrae than long bones, char-
acteristics which are confounding effects in 
these rats (Wronski et al., 1989a; Liu and 
Kalu, 1990; Liu et al., 2015). 
In rats aged 6-9 months, skeletal growth 
decreases (Kalu, 1991; Johnston and Ward, 
2015) and reaches 3.3, 1.09 (Erben, 1996) and 
< 1 µm per day in proximal tibia, caudal ver-
tebrae, and proximal femur, respectively (Li 
et al., 1991; Li and Jee, 1991; Li et al., 1997). 
It has been suggested that the minimum age 
of rats for osteoporosis studies should be 6 
months, unless one is assessing skeletal 
growth (Gasser and Willnecker, 2012). The 6‐
months old rats show the best osteoporotic re-
sponse (lower trabecular connectivity and 
higher changes of plate-like to rod-like tra-
becular bone) compared to 3‐months or 10‐
months‐old rats (Francisco et al., 2011). In ad-
dition, rats at 6-9 months of age have a stable 
level of bone turnover markers in serum and 
urine (Sims et al., 1996). Confounding effects 
of longitudinal bone growth and aging that are 
observed in rats < 6 and > 9 months, respec-
tively are not observed in rats aged 6-9 
months (Liu et al., 2015).  
Rats aged > 9 months are not appropriate 
for the ovariectomized model of osteoporosis. 
As their responses to OVX and administrated 
drugs are slow and the study time would be 
much longer resulting in high costs (Grynpas 
et al., 2000). Further, the osteoporosis effect 
that occurs after OVX, may be due to the ag-
ing process rather than the OVX per se 
(Francisco et al., 2011). In addition, unlike 
humans, low response of the cortical bone 
compared with trabecular bone has been re-
ported in rats aged > 9 months.  
To sum up, according to the literature 
available and summary shown in Table 1, 6-9 
months-old rats are recommended for their 
appropriate age for osteoporosis research with 
the 6-months-old being preferred to the 9 
months-old rats, due to lower age-related 
changes (Laib et al., 2001). 
 
Table 1: Advantages and disadvantages of OVX 
at different ages in rats (Kalu, 1991; Grynpas et 
al., 2000; Jee and Yao, 2001; Laib et al., 2001; 
Johnston and Ward, 2015; Liu et al., 2015; Jiang 
et al., 2018) 
Age of rat (months) at the time of OVX  
Parameters < 6 6-9 > 9 
Higher longitudinal bone 
growth 
Yes 
(–) 
No 
(+) 
No 
(+) 
Higher time and cost of 
the study 
No 
(+) 
No 
(+) 
Yes 
(–) 
Higher bone loss after 
OVX 
Yes 
(–) 
No 
(+) 
No 
(+) 
Confounding effects of 
age 
No 
(+) 
No 
(+) 
Yes 
(–) 
Response to 
intervention/treatment  
Yes 
(+) 
Yes 
(+) 
No 
(–) 
Higher bone loss in 
lumbar vertebral body 
after OVX  
No 
(–) 
Yes 
(+) 
Yes 
(+) 
Haversian 
systems/intercortical 
remodeling 
No 
(–) 
Yes 
(+) 
Yes 
(+) 
Low response of cortical 
bone  
Yes 
(+) 
Yes 
(+) 
No 
(–) 
Trabecular bone 
remodeling 
No 
(–) 
Yes 
(+) 
Yes 
(+) 
+, similar to postmenopausal women;  
–, unsimilar to postmenopausal women 
 
Step 3: Ovariectomy  
There are several surgical methods for 
performing OVX in rats, as well as various 
parameters for verification of OVX after sur-
gery that are discussed below. 
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Surgical methods for OVX 
Prior to surgery, fasted rats (6-12 hours) 
are anesthetized by ketamine/xylazine or 
isoflurane (Ström et al., 2012; Sankar et al., 
2014; Rigalli and Di Loreto, 2016); skin area 
is then shaved (by electric clippers), washed 
(using chlorhexidine scrub and ethanol 70 %) 
and disinfected (by povidone iodine) (Ström 
et al., 2012; Rigalli and Di Loreto, 2016). Sur-
gery should be done on a warmed pad (30-35 
°C) for preventing hypothermia (Olson and 
Bruce, 1986). Gel for eye protection is also 
used (Olson and Bruce, 1986). 
OVX in rats is done by ventral or dorsal 
skin incisions. In the ventral method, skin in-
cision is made by the single transverse lateral- 
(Sankar et al., 2014) or the single longitudi-
nal-incision (Popović et al., 2016). Duration 
of surgery and wound healing time are short 
(< 10 min and < 9 days, respectively) (Saadat 
Parhizkar and Latiff, 2008; Khajuria et al., 
2012; Sankar et al., 2014; Popović et al., 
2016; Rigalli and Di Loreto, 2016), however, 
the gastrointestinal tract is manipulated 
(Lasota and Danowska-Klonowska, 2004) 
and death rate in the first 24 h post-surgery is 
high (30 %) (Bazzigaluppi et al., 2018), 
which is why this procedure is not recom-
mended. In the dorsal method, skin is opened 
by a single midline (Olson and Bruce, 1986), 
two dorsolateral (Lasota and Danowska-
Klonowska, 2004), or a single dorsolateral in-
cision (Saadat Parhizkar and Latiff, 2008). 
Two dorsolateral skin incisions are mostly 
recommended, because there is no need to su-
ture the muscle; in addition, compared with a 
single midline incision, the skin incision is 
shorter in length (1-1.5 vs. 1-3 cm), duration 
of surgery (< 10 vs. > 15 min), and the wound 
healing time (9-10 vs. 10-14 days) (Lasota 
and Danowska-Klonowska, 2004; Park et al., 
2010; Khajuria et al., 2012).  
After surgery, the ovariectomized rats are 
housed individually for one week to avoid 
possible contamination and wound reopening 
(Khajuria et al., 2012). Administration of 
midazolam (0.5-2 mg/kg intramuscularly or 
subcutaneously every 4 to 6 hours) (Stout 
Steele and Bennett, 2011) and gentamicin (in-
tramuscularly 5 mg/kg for 5 days) or antibi-
otic powders are also suggested for reducing 
the risk of self-mutilation and infection of the 
skin after suturing (Olson and Bruce, 1986; 
Khajuria et al., 2012; Popović et al., 2016).  
Verification of OVX 
The success of OVX in rats is mostly con-
firmed by changes in the estrous cycle, hor-
monal profile (circulating concentrations of 
estradiol, luteinizing hormone (LH), follicle-
stimulating hormone (FSH) and progester-
one), body weight, as well as uterine weight 
(Hao et al., 2016). Success of OVX is also 
confirmed by failure to detect ovarian tissue 
at necropsy and by observation of marked at-
rophy of the uterine horns (Wronski et al., 
1987; Saul et al., 2016). Other parameters 
such as higher tail skin temperature are also 
observed during the first week after OVX 
(Kobayashi et al., 2000). In addition, results 
from vaginal smears show that regular estrus 
cycle disappears within 1 week after OVX, 
(Li et al., 2014; Lemini et al., 2015); details 
can be found elsewhere (Becker et al., 2005).  
Serum estradiol levels in rats, aged 6 
months during the diestrus and proestrus 
stages, are 20-30 and 90 pg/mL, respectively 
(Butcher et al., 1974; Wise and Ratner, 1980; 
Gore et al., 2000; Koebele and Bimonte-
Nelson, 2016). OVX decreases estradiol lev-
els at diestrus and proestrus stages by ~46 and 
50 % after 1 week, respectively (Li et al., 
2014; Lemini et al., 2015) and by ~60 and 
90 % after 3 weeks, respectively (Mosquera 
et al., 2015). Serum progesterone level is 
about 5-40 ng/mL during the diestrus stage 
and after OVX it decreases by ~60 % in rats 
aged 6 months (Butcher et al., 1974; Wise and 
Ratner, 1980; Gore et al., 2000; Koebele and 
Bimonte-Nelson, 2016). In addition, during 
diestrus, serum LH and FSH are 150-300 and 
5-25 ng/mL, respectively, levels that increase 
to ~2000 ng/mL after 3 weeks of OVX 
(Butcher et al., 1974; Wise and Ratner, 1980; 
Gore et al., 2000; Koebele and Bimonte-
Nelson, 2016). Therefore, measurements of 
serum estradiol, progesterone, LH and FSH 
levels before OVX and also 3 weeks after 
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OVX are recommended for verification of 
OVX. 
Despite pair-feeding, body weight in 
ovariectomized rats increased by 5-17 % at 1-
3 weeks post-OVX (Li et al., 1997; Høegh-
Andersen et al., 2004; Devareddy et al., 2008; 
Li et al., 2014; Alswat, 2017; Conley et al., 
2017; Jiang et al., 2018). After OVX, the es-
tradiol levels decline and lead to decreased 
uterine weight by ~70-80 % after 3-4 weeks 
and by ~80-85 % after 13-14 weeks (uterine 
weight is ~500-600 mg in rats aged 6 months) 
(Ke et al., 1997; Devareddy et al., 2008; 
Conley et al., 2017). Therefore, measuring 
body weight and uterine weight 3 weeks after 
surgery is recommended for further verifica-
tion of OVX in rats.  
 
Step 4: OVX-induced osteoporosis  
Response of rat bones to OVX is depend-
ent on the type of bone (trabecular vs. corti-
cal), site of bone (femur, proximal tibia, and 
lumbar vertebrae) and time after OVX (dura-
tion of estrogen deficiency) (Zhang et al., 
2007; Johnston and Ward, 2015). Osteoporo-
sis in the ovariectomized rats is confirmed by 
several methods including measurements of 
bone density, microarchitecture and bone 
turnover markers (BTMs) as discussed below. 
 
Selection of bone sites 
Effects of OVX on the bones are not uni-
form across bone sites (Francisco et al., 
2011); in addition, OVX does not induce bone 
loss in some sites such as distal tibia metaph-
ysis and caudal vertebrae (Ma et al., 1994; 
Westerlind et al., 1997; Jee and Yao, 2001). It 
has been reported that 36 weeks after OVX, 
bone loss is higher (~57-64 %) in long bones 
(including humerus, ulna, distal femur, and 
proximal tibia) compared to spine (~57-64 %) 
and cranial bones (~1-3 %) (Liu et al., 2015). 
In addition, significant bone losses in hu-
merus, femur, tibia, and spine are observed 4 
weeks post OVX, indicating that these sites 
are more sensitive to OVX (Liu et al., 2015). 
Differences in the baseline rates of bone turn-
over, rate of longitudinal bone growth, and 
mechanical loading in different bones may 
explain observed variations in bone loss in 
this model of osteoporosis (Li et al., 1997), 
suggesting that care must be taken for select-
ing bone sites studied, as not all sites behave 
in a way similar to the human (Grynpas et al., 
2000). 
Regions of interest (ROI) in rat bones are 
limited to proximal tibia, lumbar vertebrae, 
and the femur, as these are the main sites of 
fracture in humans and are clinically relevant 
(Francisco et al., 2011). Among ROI in rat 
bones, the proximal femur shares many histo-
anatomic similarities with humans (Bagi et 
al., 1997) and OVX-induced bone loss in the 
proximal femur (neck of femur) is similar to 
that observed in hip fractures of humans 
(Parfitt et al., 1983); not surprising then, that 
most researchers have focused on the proxi-
mal femur as the site of interest (Bagi et al., 
1997). The proximal tibia, the lumbar verte-
brae, and the femur are also comparable with 
that of the humans due to high sensitivity to 
OVX (Liu et al., 2015). However, these ROI 
in the rats show different patterns of bone loss 
after OVX (Wronski et al., 1988, 1989b). In 
addition, OVX-induced bone loss is observed 
earlier and is more severe in the proximal tibia 
than in the lumbar vertebrae or the femur 
(Wronski et al., 1986, 1989a, b; Francisco et 
al., 2011), which is why, the proximal tibia is 
recommended for short-term studies. 
 
Selection of bone type  
 In adult rats, different skeletal sites have 
different ratios of cortical to trabecular bone. 
The trabecular bone volumes of femoral neck, 
lumbar vertebral and proximal tibia are ap-
proximately 70 %, 40 %, and 30 %, respec-
tively (Wronski et al., 1986; Wronski et al., 
1989a; Wronski et al., 1989b; Bagi et al., 
1997). In addition, cortical and trabecular 
bone show different patterns of bone loss after 
OVX, as discussed below. 
Trabecular bone  
As shown in Figure 2, after OVX, trabec-
ular bone volume of proximal tibia, lumbar 
vertebrae and femur show different patterns 
of bone loss. OVX decreases trabecular bone 
volume in the proximal tibia by ~80 % (from 
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25-30 % to 5-7 %) at 90 days after OVX and 
by ~99 % at 540 days after OVX (Wronski et 
al., 1988, 1989b). OVX decreases trabecular 
bone volume in the femur by ~25 % between 
30-90 days and by ~50 % at 180 days post 
OVX that remain at this level until 360 days 
post OVX (Li et al., 1997). The trabecular 
bone volume in the lumbar vertebral body de-
creases by ~25 % (from 35-40 % to 30-35 %) 
during 180 days, then decreases by ~50 % be-
tween 180 and 270 days, remaining constant 
for 540 days (Wronski et al., 1989a). There-
fore, compared with the proximal tibia, bone 
loss in the vertebrae and the femur is lower 
and slower after OVX (Wronski et al., 1986, 
1989a, b). Decreases in trabecular bone vol-
ume in the ROI are accompanied by a deteri-
oration of the bone microarchitecture, as ob-
served by lower trabecular number (Tb.N) 
and thickness (Tb.Th) as well as higher tra-
becular separation (Tb.Sp) in ovariectomized 
rats, compared to controls (Li et al., 1997).  
Cortical bone  
In cortical bones, OVX increases bone 
loss and formation in the endocortical surface 
and the periosteum, respectively leading to an 
increased and decreased bone marrow cavity 
and cortical thickness, respectively (Turner et 
al., 1987; Kimmel and Wronski, 1990; Miller 
et al., 1991; Danielsen et al., 1993; Aerssens 
et al., 1996; Jee and Yao, 2001; Zhang et al., 
2007; Komori, 2015; Sharma et al., 2018). 
Decreased thickness of the endocortical sur-
face, adjacent to the marrow is the most sen-
sitive and indirect index of cortical bone loss 
(Jee and Yao, 2001; Lelovas et al., 2008) and 
is measured by the Danielsen method 
(Danielsen et al., 1993). Following OVX, no 
effect is observed on the cortical thickness un-
til 90 days (Laib et al., 2001) and the thickness 
of the endocortical surface adjacent to the 
marrow in femoral shaft decreases by only 
10 % after 180 days (Danielsen et al., 1993). 
The earliest changes in the cortical thickness 
and the medullary cavity size in the proximal 
tibia and the femoral neck are observed after 
90-120 days and 360 days post OVX, respect-
 
 
Figure 2: Effect of ovariectomy (OVX) on trabecular bone volume of proximal tibia, lumbar vertebrae 
and femur in rat 
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ively (Kimmel and Wronski, 1990; Danielsen 
et al., 1993; Ke et al., 1993; Yamamoto et al., 
1995; Li et al., 1997; Zhang et al., 2007; 
Komori, 2015). Therefore, the rate of bone 
loss in the cortical bone is much lower and 
slower than the trabecular bone (Kimmel and 
Wronski, 1990).  
To summarize, compared to cortical bone, 
the trabecular bone responds better and more 
rapidly to intervention (Grynpas et al., 2000; 
Turner, 2001) and is recommended for osteo-
porosis research in rats. 
 
Time needed for verification of  
OVX-induced osteoporosis 
In rats, after OVX, bone resorption ex-
ceeds the bone formation leading to bone loss. 
Early significant bone loss in the trabecular 
bone of the proximal tibia, the femoral neck 
and the lumbar vertebral body is observed at 
14, 30 and 60 days after OVX, respectively 
(Wronski et al., 1988, 1989a, b; Li et al., 
1997; Laib et al., 2001). Then, bone resorp-
tion and formation reach a steady state for 
which the time needed varies in rats depend-
ing on the skeletal sites and is between 90-270 
days (Jee and Yao, 2001; Lelovas et al., 
2008). Bone loss reaches a steady state at ~90 
days (Wronski et al., 1988) for the proximal 
tibia, ~270 days (~39-77 weeks) for the lum-
bar vertebral body (Wronski et al., 1989a), 
and ~270 weeks for the femoral neck (Li et 
al., 1997). It has been reported that the time 
needed for 50 % bone loss following OVX is 
30-60 days for the proximal tibia 180-270 
days for lumbar vertebral body and femoral 
neck (Wronski et al., 1989a; Zhang et al., 
2007). Therefore, according to the time 
needed for assessment of bone parameter after 
OVX, the proximal tibia is the most appropri-
ate for short-term studies.  
 
Verification of osteoporosis  
Ovariectomized-induced osteoporosis in 
rats is mainly confirmed by measurement of 
the bone density and the bone microarchitec-
ture parameters. Measurement of bone turno-
ver markers and biochemical parameters in 
serum and urine are also recommended. 
These methods in rats and humans are the 
same (Lelovas et al., 2008) and are presented 
below.  
Bone density 
Clinically, measurement of BMD is used 
to classify the onset and the extent of osteo-
porosis. As shown in Figure 3, OVX de-
creases BMD in the proximal tibia within 30 
days by ~14 % (normal level ~0.25 g/cm2), in 
the lumbar vertebrae by ~12 % (normal level 
~0.25 g/cm2), and in the femur by ~5 % (nor-
mal level ~0.21 g/cm2); these values are de-
creased to ~40 %, ~33 % and ~34 % respec-
tively, during 90 days after OVX. Based on 
human T-scores, the power of osteoporosis 
identification in rats is low whereas false neg-
ativity is high. Sirvastava et al. reported that 
the rat T-score (rT-score) has a good power 
for detection of osteoporosis; rT-score  
≤ –1.96 indicates osteoporosis in rats (Sriva-
stava et al., 2008). 
Method for measurement of bone mineral 
density 
BMD is measured by dual-energy X-ray 
absorptiometry (DEXA), which is the gold-
standard method used in clinical settings for 
diagnosing osteoporosis, bone fracture risk 
and evaluation of treatment efficacy 
(Osterhoff et al., 2016). This technique facili-
tates conducting of longitudinal studies and is 
also used to measure lean and fat mass 
(Turner, 2001; Ammann and Rizzoli, 2003). 
DEXA cannot separate trabecular from corti-
cal bone indices (Ferretti, 1995; Moisio et al., 
2003) and over half of the fractures occurring 
at a BMD level are not classified as osteopo-
rotic by DEXA (Hsu et al., 2014). BMD de-
termines only ~60-70 % of bone strength 
(Ammann and Rizzoli, 2003); hence, by it-
self, it is a relatively poor predictor of osteo-
porosis and is not the only determinant of 
bone strength; therefore, other potential deter-
minants, such as bone quality, also need to be 
considered that contribute to the severity of 
osteoporosis and bone fracture risk (Fonseca 
et al., 2014; Rosales Rocabado et al., 2018).  
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Figure 3: Effect of ovariectomy (OVX) on bone mineral density (BMD) of proximal tibia, lumbar verte-
brae and femur in rat 
 
 
 
Bone microarchitecture 
Trabecular bone microarchitecture is doc-
umented as a key component of bone quality 
and bone strength and, thus, should also be 
considered in osteoporosis research 
(Dempster, 2000; Francisco et al., 2011). A 
variety of structural indices are presented to 
characterize the properties of trabecular bone, 
including Tb.Sp, Tb.N, and Tb.Th (Francisco 
et al., 2011).  
According to literature, normal levels of 
Tb.Sp are ~190, ~260 and ~145 µm; Tb.N are 
~4.4, 3.8 and ~5.4 mm−1 and Tb.Th are ~80, 
~100 and ~90 µm in the proximal tibia, the 
lumbar vertebrae and the femur, respectively. 
As shown in Figure 4, OVX increases Tb.Sp 
by ~33 %, ~10 % and ~40 %, decreases Tb.N 
by ~22 %, ~4 % and ~19 % and decreases 
Tb.Th by ~7 %, ~1 % and ~8 %, in the proxi-
mal tibia, the lumbar vertebrae and the femur, 
respectively.  
Method for measurement of trabecular bone 
indices 
Trabecular bone indices are measured by 
microcomputed tomography (µCT), that eval-
uates both geometric (cortical and trabecular 
indices) and densitometric (i.e. BMD) param-
eters of bone and is also used to describe bone 
quality (Krause et al., 2014). The use of µCT 
in longitudinal studies is not recommended in 
some studies (Waarsing et al., 2004), because 
of the amount of radiation exposure and also 
the associated costs, both of which are higher 
than DEXA (Dare et al., 1997; Hsu et al., 
2014). However, Longo et al. (2016) reported 
that longitudinal scanning of tibia by µCT 
with low amount of radiation exposure (low 
resolution) at different times within the study 
window (13, 17, 21 and 25 weeks after OVX) 
did not cause adverse effects on trabecular in-
dices of tibia.  
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Figure 4: Effect of ovariectomy (OVX) on trabecular number (Tb.N) (A), trabecular separation (Tb.Sp) 
(B), and trabecular thickness (Tb.Th) (C) of proximal tibia, lumbar vertebrae and femur in rat
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Bone turnover markers  
Measurement of bone turnover markers 
(BTMs) in serum and urine, released during 
the formation and resorption of bone, are rec-
ommended for the verification of osteoporo-
sis (Frolik et al., 1996). Animals should be 
fasted for 24-36 hours before blood collection 
and 12 hours before 24-hour urine collection 
for measurements of BTMs (Sims et al., 
1996). Measurement of BTMs characterizes 
acute changes in bone turnover in the whole 
skeleton, however these do not provide any 
information regarding bone mass or bone 
strength; also, a number of interfering factors 
such as circadian rhythm, and food intake 
could affect BTMs (Morris et al., 1992; Frolik 
et al., 1996; Schlemmer and Hassager, 1999; 
Seibel, 2003). 
Estrogen deficiency is associated with 
high levels of both bone-resorption and bone-
formation markers (Garnero et al., 1996; 
Charatcharoenwitthaya et al., 2007). In rats, 
the bone formation markers are alkaline phos-
phatase (ALP), osteocalcin (OC), and amino-
terminal propeptides of procollagen type I 
(P1NP). These are preferentially measured in 
the serum, while bone resorption markers in-
cluding carboxy-terminal cross-linking telo-
peptide of type I collagen (CTX), pyridinoline 
(PYD), and deoxypyridinoline (DPD) are 
measured in both serum and urine (Dick et al., 
1996; Kuo and Chen, 2017).  
According to literature, normal levels of 
OC, ALP and P1NP are ~20 µg/L, ~38-78 
U/L and ~75 ng/mL, respectively in 6-
months-old female rats. OVX increases serum 
OC and ALP by 20-30 % and 30-60 % after 
1-6 weeks (Dick et al., 1996; Schulz and 
Morris, 1999; Davey and Morris, 2005). 
P1NP is increased by 13 % and 106 % 12 and 
18 weeks  after OVX, respectively (Smith et 
al., 2014). In addition, urine PYD increases 
by 35-50 % after 1-3 weeks and urine DPD 
increases by 35-50 % (Morris et al., 1992; 
Sims et al., 1996; Schulz and Morris, 1999; 
Davey and Morris, 2005), and 172 % during 
1-3 and 12 weeks  after OVX, respectively 
(Smith et al., 2014). CTX is elevated by 
74.4 % during 18 weeks after OVX (Wei et 
al., 2014). Among these markers, P1NP (a 
bone formation marker) and CTX (a bone re-
sorption marker) are the most reliable markers 
proposed by the International Osteoporosis 
Foundation (IOF) and the International Fed-
eration of Clinical Chemistry and Laboratory 
Medicine because of having smaller circadian 
variations, more stability at room tempera-
ture, and a good assay precision (Shetty et al., 
2016). Serum phosphate increases in ovariec-
tomized rats from week 1 and remains ele-
vated until week 9 (Morris et al., 1992; Dick 
et al., 1996; Sims et al., 1996), then restores 
to normal levels at week 17 (Li et al., 2013). 
In addition, although urine phosphate in-
creases one week after OVX, it returns to nor-
mal levels by the third week (Dick et al., 
1996). Results regarding serum calcium lev-
els are controversial, but in the most studies 
unchanged levels of serum calcium have been 
reported at 1 (Sims et al., 1996), 2 (Davey and 
Morris, 2005), and 17 weeks (Li et al., 2013) 
post OVX. In addition, urine calcium levels 
are increased one week after OVX returning 
however to normal levels within 2-6 weeks 
(Morris et al., 1992; Dick et al., 1996). 
 
POTENTIAL LIMITATIONS FOR  
USING OVARIECTOMIZED RAT 
MODEL OF OSTEOPOROSIS 
Potential limitations and solutions to the 
use of ovariectomized rat model of osteopo-
rosis are presented in Table 2. Major potential 
drawbacks are the presence of longitudinal 
bone growth in mature rats after OVX, higher 
modeling activity, and absence of naturally 
fragility fracture in the rat skeleton. 
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Table 2: Potential limitations and proposed solutions for using the ovariectomized rat model of osteo-
porosis 
Limitation Solution 
Longitudinal bone growth in 
mature rats after OVX 
(Dawson, 1925) 
 Use the 6 months aged rats (Turner, 2001). 
 Use skeletal sites with low longitudinal growth such as lumbar 
vertebrae (Turner, 2001). 
 Avoid measurement of bone parameters adjacent to the epi-
physeal growth plate in young rats (1 and 0.5 mm distal to the 
growth plate in the proximal tibia and lumbar vertebrae, respec-
tively (WHO Scientific Group on Prevention and Management of 
Osteoporosis, 2003). 
 Use a control group to differentiate the gain or loss of bone 
mass attributed to age (Jee and Yao, 2001; WHO Scientific 
Group on Prevention and Management of Osteoporosis, 2003).
Low level of Haversian re-
modeling in rats (Grynpas et 
al., 2000; Turner, 2001; WHO 
Scientific Group on Preven-
tion and Management of Os-
teoporosis, 2003) 
 Use the 6-9 months aged rat model that has a Haversian re-
modeling system (Turner, 2001). 
 Ignore this limitation because of bone loss in the Haversian sys-
tem plays a minor role in postmenopausal osteoporosis and tra-
becular bone loss plays a major role in postmenopausal osteo-
porosis (Turner, 2001; Lelovas et al., 2008). 
High modeling activity in 
the rat skeleton (Grynpas et 
al., 2000; Lelovas et al., 2008) 
 
 
 
 
 Use 6 months aged rats (Jee and Yao, 2001; Lelovas et al., 
2008). 
 Select bone sites in which transition from modeling to remodel-
ing activity is done (Jee and Yao, 2001; Lelovas et al., 2008):  
 In the lumbar vertebrae at age 3 months for trabec-
ular bones and at age 3-6 months for cortical bones. 
 In the proximal tibia metaphysis at age 6-9 months 
for trabecular bones and at age 9-12 months for 
cortical bone. 
Absence of naturally fragil-
ity fractures in rat (Jee and 
Yao, 2001) 
 Use  mechanical testing of bone strength in various bones 
(Jee and Yao, 2001); low bone strength in rats is observed 
in trabecular bone (vertebral) at age 3 months (Mosekilde 
et al., 1993; Yoshitake et al., 1999) and in cortical bone 
(femoral neck and diaphysis) at aged 3 and 9 months post–
OVX, respectively (Turner et al., 1987; Aerssens et al., 
1993; Peng et al., 1994; Jiang et al., 1997; Yoshitake et al., 
1999). 
 
 
CONCLUSION 
To conclude, although no animal model is 
perfect, the similarities in response to estro-
gen deficiency and therapeutic agents be-
tween the human and rat skeleton, have made 
the ovariectomized rat model an appropriate 
model in osteoporosis research. Current data 
show that the responses of the rat bones to 
OVX are dependent on the age of rat at the 
time of OVX (rats aged 6 months are more 
appropriate), the type of bone (trabecular 
bone recommended), the site of bone (proxi-
mal tibia, lumbar vertebrae and femur recom-
mended) and the duration of OVX (14, 30 and 
60 days after OVX recommended for proxi-
mal tibia, femoral neck, and lumbar vertebral 
body).  
Some important areas however remain to 
be elucidated regarding this model, including 
molecular mechanisms involved in OVX-in-
duced osteoporosis. In addition, the effects of 
some diseases on the ovariectomized rat 
model of osteoporosis, and the combination 
effects of estrogen deficiency plus a low cal-
cium diet, for acceleration of bone loss in rats 
warrant further clarification. 
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